BNP Paribas Exane cuts Itron stock price target on valuation shift
BNP Paribas Exane reduced its price target for Itron Inc. (ITRI) to $105 from $115, citing a valuation multiple adjustment. The stock trades at $94.55, below the analyst consensus range. The firm notes increased spending on AMI meter replacements, projecting significant revenue growth for Itron. The company recently reported Q3 2026 earnings that exceeded expectations, with revenue of $599.3 million and non-GAAP EPS of $1.94.
How this was made
The 30-second read
Why it matters
The earnings beat supports the Outperform rating, but the analyst's target reduction tempers upside expectations.
Market read
Analyst target cut provides fresh valuation insight for traders; modest impact on Itron's price trajectory.
What to watch
Potential upside from upcoming large utility contracts and long‑term growth in AMI replacement programs.
Background
Itron reported Q3 2026 earnings that beat expectations, with non‑GAAP EPS of $1.94 and revenue of $599.3 million.
Ticker impact
BNP Paribas Exane lowered Itron's price target to $105 from $115 while keeping an Outperform rating.
potential downside as investors price in the lower target
Target reduction signals valuation concerns; market may react with modest price pressure.
Market effects
Utility metering sector may see modest re‑rating as analysts adjust expectations for AMI meter replacement spend.
Limited to U.S. utility‑related stocks; no broad regional effect.
Low global impact; primarily affects Itron and peers in the smart‑meter space.
Counterpoint
The target cut may be overly cautious given strong Q3 earnings and growing meter replacement pipeline.
Key entities
- AnalystBNP Paribas Exane
Equity research firm that issued the price target revision.
- CompanyItron Inc.
Provider of smart‑metering and utility analytics solutions.
